Marchés français ouverture 2 h 12 min

Quantum Genomics Societe Anonyme (ALQGC.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
2,59500,0000 (0,00 %)
À la clôture : 5:35PM CEST
Plein écran
Clôture précédente2,5950
Ouverture2,5950
Offre0,0000 x 0
Vente0,0000 x 0
Var. jour2,5800 - 2,6250
Sur 52 semaines1,5100 - 5,5900
Volume63 977
Volume moyen190 124
Cap. boursière48,598M
Bêta (mensuel sur 5 ans)0,84
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-0,5030
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 an9,86
  • Cercle Finance

    Quantum Genomics: début du recrutement pour l'étude FRESH

    (CercleFinance.com) - Quantum Genomics annonce le recrutement du premier patient dans l'étude FRESH dans l'hypertension artérielle difficile à traiter ou résistante, étude menée conjointement avec le laboratoire ...

  • Globe Newswire

    Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension

    PARIS and NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, today announced the enrollment of the first patient in the Company’s FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat(1) or resistant(2) hypertension. The study is being conducted jointly with its partner in Latin America, the Biolab Sanus Pharmaceutical laboratory.“We are thrilled to enroll the first patient in our pivotal phase III study of firibastat in patients with difficult to treat and resistant hypertension,” said Jean-Philippe Milon, chief executive officer of Quantum Genomics. “We believe firibastat has the potential to meaningfully improve the treatment regimen for this large, and currently underserved population of patients and we look forward to top-line results by the end of 2021.”The FRESH study is a randomized, double-blind, placebo-controlled pivotal phase III study, which will be conducted in approximately 70 hospitals worldwide and enroll 502 patients with difficult-to-treat or resistant hypertension. Patients will receive either 500mg of firibastat or placebo twice daily for 3 months, in addition to their current treatment. The primary endpoint will be the reduction in systolic automated office blood pressure (AOBP) from baseline.The study is being conducted in Europe (France, Germany, Poland, Spain and the Czech Republic), Canada, the United States, and Latin America (Brazil and Mexico), with the support of two contract research organizations: PRA Health Sciences in Europe, Canada, the U.S. and Azidus in Latin America.The Company received all necessary ethical and regulatory approvals to conduct its trial in the majority of countries and has been able to open the first centers, while taking all necessary safety measures and precautions for trial participants and facility workers amidst the ongoing COVID-19 pandemic.The FRESH Phase III trial design was based on results of the previously completed Phase II NEW HOPE study, which demonstrated the efficacy of firibastat in a hypertensive and high cardiovascular risk patient population, 38% of which was of African American descent, and the majority of which was obese: two patient populations that are frequently affected by resistant hypertension, and have disease states that are often in the difficult-to-treat category. The company received FDA’s concurrence on the trial design in late 2019.(1) Patients not controlled despite two antihypertensive classes, including a diuretic, at maximum tolerated doses. (2) Patients not controlled despite at least three antihypertensive classes, including a diuretic, at maximum tolerated doses.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF) For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContacts Quantum Genomics  Jean-Philippe Milon CEO jean-philippe.milon@quantum-genomics.comBenoît Gueugnon CFO benoit.gueugnon@quantum-genomics.com So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 430-7576 | Daniel@lifesciadvisors.comMike Tattory Media Relations and Scientific Communications +1 (609) 802-6265 | mtattory@lifescicomms.com

  • Globe Newswire

    Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients

    Results demonstrate that firibastat could be used in hypertensive and heart failure patients with concomitant renal dysfunction, subject to dose adjustment.PARIS and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and resistant hypertension and heart failure, announced results from an interim analysis of findings from QGC001/1QG4, its study of firibastat in end-stage renal failure (ESRD) patients. The interim analysis shows that, because of a slower elimination (longer half-life [t ½ ]), exposure (AUC) to firibastat and its main metabolites is relatively more important in ESRD patients compared to healthy volunteers, without any significant increase in peak concentration (Cmax). Firibastat was well tolerated in the study and no related adverse event was recorded. No significant deterioration of the renal function was observed in ESRD patients, which strengthen safety conclusions of the previous studies, particularly the NEW-HOPE trial conducted in hypertensive patients without renal dysfunction. The pharmacokinetic parameters obtained and the good tolerance of the product suggest that a simple dose adjustment could allow the use of firibastat in patients with chronic renal failure.“These interim results provide important insights since we know now how to adapt the firibastat dose to enroll patients with severe to end-stage renal failure in our clinical studies,” said Bruno Besse Chief Medical Officer of Quantum Genomics. “this will confirm that firibastat could be used to treat heart failure patients and treatment-resistant hypertensive patients even in the case of concomitant renal dysfunction, including end-stage, where very limited options are available.”Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics commented: “Renal failure is a common comorbidity in patients with hypertension and with heart failure. The use of firibastat in these patients could expand its market in resistant hypertension and heart failure by 15 to 20%.” Study QGC001/1QG4 was designed to compare pharmacokinetic parameters of firibastat and its main metabolites in patients with ESRD (estimated glomerular filtration rate [eGFR] <15 mL/min/m²) to those of healthy volunteers after a single oral dose of firibastat (500 mg).All 14 patients with ESRD have been recruited in the study and had a mean age of 46±2 years with mean eGFR of 12±3 mL/min/m². To date, six of 14 healthy volunteers have been recruited and treated, and had a mean age of 43±12 years with a mean eGFR of 99±22 mL/min/m².According to the Health Authorities recommendation, healthy volunteers’ enrollment was stopped because of the COVID-19 pandemic and will resume after the crisis. Final analysis will be performed once all healthy volunteers have been enrolled, but since data for all ESRD patients are already available, this is not expected to significantly change the study conclusions.Chronic kidney disease (CKD) is a well-known complication of hypertension, especially when blood pressure is uncontrolled. Renal dysfunction occurs in roughly 20% of patients with treatment-resistant hypertension.1 This feature comorbidity makes these patients’ treatment even more difficult because several classes of hypertension drugs are not recommended or are contra-indicated, for example with spironolactone.CKD is also a frequent comorbidity in heart failure (HF). A prospective study found that 16% and 40% of HF patients have concomitant severe or moderate renal dysfunction, respectively.2 This is also a factor of poor prognosis, with each 1 mL/min/m2 decrease in eGFR resulting in a 1% mortality increase. Similarly, for myocardial infarction (MI), there is a 20% higher mortality rate following MI in patients ESRD.3 1 Acharya T et al. Resistant Hypertension and Associated Comorbidities in a Veterans Affairs Population J Clin Hypertens (Greenwich). 2014;16:741–745.2 Mc Alister F. et al. Renal Insufficiency and Heart Failure. Prognostic and Therapeutic Implications From a Prospective Cohort Study. Circulation. 2004;109:1004-10093 Sundaram V. et al. Impact of comorbidities on peak troponin levels and mortality in acute myocardial infarction. Heart 2020;106:677–685.About Quantum GenomicsQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF) For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContacts Quantum Genomics  Jean-Philippe Milon CEO jean-philippe.milon@quantum-genomics.comBenoît Gueugnon CFO benoit.gueugnon@quantum-genomics.com     So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr    LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 535-7746 | Daniel@lifesciadvisors.com Mike Tattory Media Relations and Scientific Communications +1 (609) 802-6265 | mtattory@lifescipublicrelations.com

En utilisant Yahoo vous acceptez les cookies de Yahoo/ses partenaires aux fins de personnalisation et autres usages